Medivir strengthens pipeline with acquisition of Novadex' preclinical antiviral assets
This article was originally published in Scrip
Executive Summary
Medivir has acquired from Novadex Pharmaceuticals a portfolio of preclinical antiviral programs, including hepatitis C and prodrug technologies. The company said the move will 'further strengthen its pipeline and capabilities in the antiviral disease area'.